1. 17LBA Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC. (September 2015) Authors: Rini, B.; Stenzl, A.; Zdrojowy, R.; Kogan, M.; Shkolnik, M.; Oudard, S.; Weikert, S.; Bracarda, S.; Crabb, S.; Bedke, J.; Ludwig, J.; Maurer, D.; Mendrzyk, R.; Mahr, A.; Fritsche, J.; Weinschenk, T.; Singh, H.; Kirner, A.; Reinhardt, C.; Eisen, T. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S718 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2500 Orteronel (Ort) maintenance therapy in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) and non-progressive disease after first-line docetaxel (Doc) therapy: Results of a multicenter randomized double-blind placebo-controlled phase III trial (SAKK 08/11). Issue 3 (September 2015) Authors: Cathomas, R.; Crabb, S.; Kenner, H.; Mark, M.; Rothermundt, C.; Elliott, T.; Winterhalder, R.; Von Burg, P.; Berardi Vilei, S.; Hayoz, S.; Rauch, D.; Roggero, E.; Stenner, F.; Berthold, D.; Erdmann, A.; Fischer, N.; Manetsch, G.; Gillessen, S. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S473 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2607 Predicting venous thromboembolism (VTE) in metastatic urothelial tract tumors (UTT). (September 2015) Authors: Ramos, J.; Casey, M.; Bamias, A.; De Giorgi, U.; Bellmunt, J.; Harshman, L.; Ladoire, S.; Wong, Y.N.; Alva, A.; Necchi, A.; Recine, F.; Vaishampayan, U.; Niegisch, G.; Pal, S.; Crabb, S.; Golshayan, A.; Srinivas, S.; Rosenberg, J.; Galsky, M.; Yu, E. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S514 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 2619 Patterns and potential benefit of adjuvant chemotherapy for residual muscle invasive disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC). (September 2015) Authors: Harshman, L.; Werner, L.; Wong, Y.N.; Yu, E.; Alva, A.; Crabb, S.; Powles, T.; Rosenberg, J.; Baniel, J.; Vaishampayan, U.; Berthold, D.; Ladoire, S.; Hussain, S.; Milowsky, M.; Agarwal, N.; Necchi, A.; Pal, S.; Recine, F.; Bellmunt, J.; Galsky, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S518 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A Survey of the Real-world Patient-reported Experience of Follow-up Practices Following Radical Surgery or Radiotherapy for Muscle-invasive Bladder Cancer (MIBC). Issue 2 (February 2023) Authors: Hack, J.; Crabb, S.; Costin, M.; Kelly, P.; Makaroff, L.; Douglas, J. Journal: Clinical oncology Issue: Volume 35:Issue 2(2023) Page Start: e238 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Discursive practices around the body of the female athlete: An analysis of sport psychology interactions in elite sport. (July 2019) Authors: Cosh, S.; Tully, P.J.; Crabb, S. Journal: Psychology of sport and exercise Issue: Volume 43(2019) Page Start: 90 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗